510(k) · Cleared
ClearedAudit MicroControls Linearity LQ Cystatin-C
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Aalto Scientific, Ltd. · JJX Single (Specified) Analyte Controls (Assayed And Unassayed)
Cleared on Jan 23, 2015 as substantially equivalent to K130157 (Aalto Scientific, Ltd., 2013) after a 37-day review. Its family tree reaches back 5 generations to 1991.
- Decided
- Jan 23, 2015
- Review
- 37 days
- Class
- Class I
- Product code
- JJX
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 5 generations to K910440 (1991). No later device cites it as a predicate yet.
- Root · 5 generations backK910440 Document Reflectance II Linearity Test SetCasco Standards · 1991
- 4 generations backK023410 Validate Chem 10 Calibration Verification Test Set, Model 110Maine Standards Co. · 2003
- 3 generations backK042318 Audit Microcv General Chemistry Linearity SetAalto Scientific, Ltd. · 2004
- 2 generations backK101427 Audit Microcv HS-CRP Linearity SetAalto Scientific, Ltd. · 2010
- 1 generation backK130157 Audit Microcv Beta-Hydroxybutyric Acid Linearity SetAalto Scientific, Ltd. · 2013
- This deviceK143571 Audit MicroControls Linearity LQ Cystatin-CAalto Scientific, Ltd. · 2015
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −5 | K910440 | Document Reflectance II Linearity Test Set | Casco Standards | 1991 | — |
| −4 | K023410 | Validate Chem 10 Calibration Verification Test Set, Model 110 | Maine Standards Co. | 2003 | — |
| −3 | K042318 | Audit Microcv General Chemistry Linearity Set | Aalto Scientific, Ltd. | 2004 | — |
| −2 | K101427 | Audit Microcv HS-CRP Linearity Set | Aalto Scientific, Ltd. | 2010 | — |
| −1 | K130157 | Audit Microcv Beta-Hydroxybutyric Acid Linearity Set | Aalto Scientific, Ltd. | 2013 | — |
| 0 (this device) | K143571 | Audit MicroControls Linearity LQ Cystatin-C | Aalto Scientific, Ltd. | 2015 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JJX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K130157 | Audit Microcv Beta-Hydroxybutyric Acid Linearity SetSummary page 4…ce Classification: Class I, Reserved Product Code: JJX Regulation Number: 21CFR862.1660 C. Device to Which Substantial Equivalence is Claimed K130157 Audit® MicroCV™ Beta-Hydroxybutyric Acid Linearity Set D. Intended Use The Linearity LQ Cystatin-C is an assayed quality con… | 2013 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 24 years and passes through 3 companies; a new generation was cleared every 2.2 years on median.
- None of the 5 ancestors has a recall.
- 2 other devices also cite its predicate K130157.
How does its category compare?
All JJX devicesJJX Single (Specified) Analyte Controls (Assayed And Unassayed): FDA decisions, review times, recalls and adverse event reports over 20 years. 2015, this device’s year, is highlighted.
FDA decisions per year · JJX
2in 2017
2026 to Oct 25, outlined.
Median 510(k) review, days · JJX
31in 2016
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · JJX
1in 2021
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · JJX
22in 2025
MAUDE reports naming product code JJX, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 6 | 53 | 3 | 2 |
| 2008 | 8 | 52 | 3 | 0 |
| 2009 | 17 | 80 | 0 | 1 |
| 2010 | 24 | 80 | 3 | 6 |
| 2011 | 19 | 62 | 2 | 62 |
| 2012 | 15 | 40 | 0 | 32 |
| 2013 | 19 | 37 | 0 | 51 |
| 2014 | 22 | 30 | 1 | 48 |
| 2015 | 11 | 65 | 1 | 67 |
| 2016 | 6 | 31 | 2 | 37 |
| 2017 | 2 | — | 0 | 19 |
| 2018 | 0 | — | 2 | 35 |
| 2019 | 0 | — | 0 | 82 |
| 2020 | 0 | — | 0 | 77 |
| 2021 | 0 | — | 1 | 43 |
| 2022 | 0 | — | 0 | 24 |
| 2023 | 0 | — | 0 | 22 |
| 2024 | 0 | — | 0 | 30 |
| 2025 | 0 | — | 0 | 22 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Linearity LQ Cystatin-C is an assayed quality control material intended to simulate human patient samples for use in
determining linearity, calibration verification, and the verification of reportable range for the Cystatin-C analyte.
The Linearity LQ Cystatin-C is for In Vitro Diagnostic use only.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K143571 · printed Nov 4, 2026
Cite this page
510(k) Report. “K143571: Audit MicroControls Linearity LQ Cystatin-C.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K143571
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026